JPMorgan Chase & Co. reiterated their overweight rating on shares of Aviva (LON:AV – Get Rating) in a report published on Tuesday, Marketbeat.com reports.
Several other equities research analysts have also recently commented on AV. Deutsche Bank Aktiengesellschaft reaffirmed a buy rating and issued a GBX 485 ($5.83) target price on shares of Aviva in a research report on Thursday, November 10th. Berenberg Bank raised their price target on shares of Aviva from GBX 540 ($6.49) to GBX 546 ($6.57) and gave the company a buy rating in a report on Monday, January 30th. Finally, Barclays cut their price target on Aviva from GBX 564 ($6.78) to GBX 560 ($6.73) and set an equal weight rating for the company in a research note on Tuesday, February 14th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, Aviva presently has a consensus rating of Moderate Buy and a consensus target price of GBX 520.86 ($6.26).
Aviva Stock Down 0.1 %
Shares of LON AV opened at GBX 448.70 ($5.40) on Tuesday. The business has a 50-day simple moving average of GBX 446.78 and a two-hundred day simple moving average of GBX 434.51. The company has a quick ratio of 1.57, a current ratio of 2.82 and a debt-to-equity ratio of 47.99. Aviva has a 52 week low of GBX 341.92 ($4.11) and a 52 week high of GBX 606.58 ($7.29). The company has a market cap of £12.61 billion, a P/E ratio of -4,081.82, a P/E/G ratio of 5.90 and a beta of 1.03.
Insider Activity
About Aviva
Aviva plc provides various insurance, retirement, investment, and savings products in the United Kingdom, Ireland, Canada, and internationally. The company offers life insurance, long-term health and accident insurance, savings, pension, and annuity products, as well as pension fund business and lifetime mortgage products.
Further Reading
- Under-the-Radar Azul SA Takes Flight on Robust Travel Demand
- Market Gets “Powelled”: S&P 500 Confirms Resistance
- Ulta Insiders Hold Tight: Sell-Siders Buy
- Rivian Plummets, But Is This 2023’s Greatest Buying Opportunity?
- Potential Earnings Have Rated Ambrx Biopharma a Moderate Buy
Receive News & Ratings for Aviva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aviva and related companies with MarketBeat.com's FREE daily email newsletter.